These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10407077)

  • 1. Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties.
    Fonseca MJ; Haisma HJ; Klaassen S; Vingerhoeds MH; Storm G
    Biochim Biophys Acta; 1999 Jul; 1419(2):272-82. PubMed ID: 10407077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
    Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
    Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.
    Vingerhoeds MH; Haisma HJ; van Muijen M; van de Rijt RB; Crommelin DJ; Storm G
    FEBS Lett; 1993 Dec; 336(3):485-90. PubMed ID: 8282116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
    Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
    Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review on novel targeted enzyme drug delivery systems: enzymosomes.
    Kumar D; Sachdeva K; Tanwar R; Devi S
    Soft Matter; 2024 Jun; 20(23):4524-4543. PubMed ID: 38738579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymerizable Fab' antibody fragments for targeting of anticancer drugs.
    Lu ZR; Kopecková P; Kopecek J
    Nat Biotechnol; 1999 Nov; 17(11):1101-4. PubMed ID: 10545917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superoxide dismutase enzymosomes: carrier capacity optimization, in vivo behaviour and therapeutic activity.
    Corvo ML; Marinho HS; Marcelino P; Lopes RM; Vale CA; Marques CR; Martins LC; Laverman P; Storm G; Martins MB
    Pharm Res; 2015 Jan; 32(1):91-102. PubMed ID: 25037861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
    Haisma HJ; van Muijen M; Pinedo HM; Boven E
    Cell Biophys; 1994; 24-25():185-92. PubMed ID: 7736523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells.
    Ohradanova-Repic A; Nogueira E; Hartl I; Gomes AC; Preto A; Steinhuber E; Mühlgrabner V; Repic M; Kuttke M; Zwirzitz A; Prouza M; Suchanek M; Wozniak-Knopp G; Horejsi V; Schabbauer G; Cavaco-Paulo A; Stockinger H
    Nanomedicine; 2018 Jan; 14(1):123-130. PubMed ID: 28939491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
    Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
    Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes.
    Shahinian S; Silvius JR
    Biochim Biophys Acta; 1995 Nov; 1239(2):157-67. PubMed ID: 7488620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
    Nässander UK; Steerenberg PA; Poppe H; Storm G; Poels LG; De Jong WH; Crommelin DJ
    Cancer Res; 1992 Feb; 52(3):646-53. PubMed ID: 1732053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
    Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
    Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells.
    Li T; Amari T; Semba K; Yamamoto T; Takeoka S
    Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of immunoliposomes directed against human ovarian carcinoma.
    Nässander UK; Steerenberg PA; De Jong WH; Van Overveld WO; Te Boekhorst CM; Poels LG; Jap PH; Storm G
    Biochim Biophys Acta; 1995 Apr; 1235(1):126-39. PubMed ID: 7718600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.